{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:05:28Z","timestamp":1795039528217,"version":"4.10.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1414,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1365-2230.2011.04169.x","type":"journal-article","created":{"date-parts":[[2011,10,18]],"date-time":"2011-10-18T13:44:14Z","timestamp":1318945454000},"page":"132-135","source":"Crossref","is-referenced-by-count":11,"title":["Refractory aphthous ulceration treated with thalidomide: a report of 10\u2003years\u2019 clinical experience"],"prefix":"10.1093","volume":"37","author":[{"given":"S.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,10,18]]},"reference":[{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1529-8019.2007.00132.x","article-title":"Dermatologic therapeutics: thalidomide. A practical guide","volume":"20","author":"Rosenbach","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of actions and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0248-8663(99)80105-2","article-title":"Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients","volume":"20","author":"De Wazi\u00e8res","year":"1999","journal-title":"Rev Med Interne"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02054255","article-title":"Treatment of Beh\u00e7et\u2019s disease with thalidomide","volume":"5","author":"Hamza","year":"1986","journal-title":"Clin Rheumatol"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.53.12.828","article-title":"Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Beh\u00e7et\u2019s disease: use of neurophysiological studies to detect thalidomide neuropathy","volume":"53","author":"Gardner-Medwin","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et\u2019s syndrome: a randomised, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2133.1986.tb05753.x","article-title":"Thalidomide in the treatment of neuro-Beh\u00e7et\u2019s syndrome","volume":"115","author":"Ranselaar","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archderm.1990.01670310085012","article-title":"Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis","volume":"126","author":"Revuz","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2230.2011.04169.x-BIB10|cit10","first-page":"177","article-title":"Use of thalidomide in leprosy","volume":"13","author":"Crawford","year":"1994","journal-title":"Adverse Drug React Toxicol Rev"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2230.2011.04169.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2230.2011.04169.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:09:48Z","timestamp":1676383788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/37\/2\/132\/6622735"}},"subtitle":["Refractory aphthous ulceration treated with thalidomide"],"short-title":[],"issued":{"date-parts":[[2011,10,18]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2230.2011.04169.x","relation":{},"ISSN":["0307-6938"],"issn-type":[{"value":"0307-6938","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10,18]]}}}